Oblenio Bio

Private

#Autoimmune Disease #B-cell Mediated Disease #T-cell Engagers #Trispecific Antibodies

Oblenio Bio is a biotechnology company developing trispecific T-cell engager (TCE) therapies for autoimmune diseases. The company raised a $62M Series B led by Pfizer Ventures in 2026 to advance its lead candidate LBL-051, a trispecific TCE targeting BCMA, CD19, and CD20 for B-cell driven autoimmune disorders.

Company Info

Sector:Biotechnology / Autoimmune Disease / T-cell Engagers

Headquarters:Cambridge, Massachusetts, USA

Founded:2022

Website:www.obleniobio.com/

Clinical Development Pipeline

LBL-051

Target: BCMA x CD19 x CD20 trispecific T-cell engager

B-cell driven autoimmune disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Autoimmune disease company Oblenio Bio clinches $62M led by Pfizer Ventures ↗

Autoimmune disease company Oblenio Bio clinches $62M led by Pfizer Ventures

Leadership Team

Samantha Truex

Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →